NASDAQ:CBLI - Cleveland BioLabs Stock Price, Price Target & More

$2.89 +0.05 (+1.76 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$2.84
Today's Range$2.79 - $2.97
52-Week Range$2.24 - $4.47
Volume6,580 shs
Average Volume17,183 shs
Market Capitalization$32.03 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.62

About Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs logoCleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and the Russian Federation. The company's advanced product candidate is entolimod, a Toll-like receptor 5 (TLR5) agonist that is used to prevent death from acute radiation syndrome, and as an oncology drug. It is also developing CBLB612, a pharmacologically optimized synthetic molecule that structurally mimics naturally occurring lipopeptides of Mycoplasma, and activates NF-kB pro-survival and immunoregulatory signaling pathways; and Mobilan, a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. In addition, the company develops CBL0137, a small molecule with a multi-targeted mechanism of action used for the treatment of various types of cancer. Cleveland BioLabs, Inc. has strategic partnerships with The Cleveland Clinic and Roswell Park Cancer Institute. The company was founded in 2003 and is headquartered in Buffalo, New York.

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CBLI
CUSIPN/A
Phone716-849-6810

Debt

Debt-to-Equity RatioN/A
Current Ratio4.33%
Quick Ratio4.33%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.95 million
Price / Sales16.72
Cash FlowN/A
Price / CashN/A
Book Value$0.66 per share
Price / Book4.38

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-9,700,000.00
Net Margins-498.31%
Return on Equity-104.66%
Return on Assets-83.32%

Miscellaneous

Employees19
Outstanding Shares11,280,000

How to Become a New Pot Stock Millionaire

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs (NASDAQ:CBLI) posted its earnings results on Tuesday, March, 6th. The biotechnology company reported ($0.10) EPS for the quarter. The biotechnology company earned $0.87 million during the quarter. Cleveland BioLabs had a negative net margin of 498.31% and a negative return on equity of 104.66%. View Cleveland BioLabs' Earnings History.

Who are some of Cleveland BioLabs' key competitors?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:
  • Dr. Yakov N. Kogan Ph.D., MBA, Chief Exec. Officer and Interim Principal Financial Officer (Age 45)
  • Dr. Langdon L. Miller M.D., Pres and Chief Medical Officer (Age 64)
  • Dr. Andrei V. Gudkov Ph.D., D.Sci., Chief Scientific Officer (Age 62)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

Has Cleveland BioLabs been receiving favorable news coverage?

Media stories about CBLI stock have trended somewhat positive on Monday, Accern reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cleveland BioLabs earned a media sentiment score of 0.16 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.54 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Cleveland BioLabs' major shareholders?

Cleveland BioLabs' stock is owned by many different of institutional and retail investors. Top institutional investors include ALPHA CAPITAL ANSTALT (1.77%) and ALPHA CAPITAL ANSTALT (1.77%). View Institutional Ownership Trends for Cleveland BioLabs.

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $2.89.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $32.03 million and generates $1.95 million in revenue each year. Cleveland BioLabs employs 19 workers across the globe.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]


MarketBeat Community Rating for Cleveland BioLabs (CBLI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  80 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cleveland BioLabs (NASDAQ:CBLI) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
(Data available from 4/23/2016 forward)

Earnings

Cleveland BioLabs (NASDAQ:CBLI) Earnings History and Estimates Chart

Earnings by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018Q4 2017($0.10)$0.87 millionViewN/AView Earnings Details
11/14/2017Q3 2017($0.11)$0.30 millionViewN/AView Earnings Details
8/14/2017Q2 2017($0.50)$0.21 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.15)$0.58 millionViewN/AView Earnings Details
2/22/2017Q4 2016($0.11)$0.99 millionViewN/AView Earnings Details
11/14/2016Q3 2016$0.10$1.14 millionViewN/AView Earnings Details
8/15/2016Q2($0.17)$0.58 millionViewN/AView Earnings Details
5/16/2016Q116($0.06)$0.81 millionViewN/AView Earnings Details
2/22/2016Q4 2015($0.15)$1.27 millionViewN/AView Earnings Details
11/5/2015Q315$0.31$415.00 million$0.50 millionViewN/AView Earnings Details
8/12/2015Q215($0.72)$562.10 million$329.90 millionViewListenView Earnings Details
5/6/2015Q115($1.14)$1.33 million$0.61 millionViewN/AView Earnings Details
2/24/2015Q114($1.02)$3.87 million$1.39 millionViewN/AView Earnings Details
11/5/2014Q3 2014($1.20)$0.42 millionViewN/AView Earnings Details
8/7/2014Q2 2014($1.80)$0.56 millionViewN/AView Earnings Details
5/8/2014Q1 2014($1.00)($1.20)$2.86 million$1.33 millionViewN/AView Earnings Details
3/11/2014Q413($0.12)($0.01)$1.74 million$3.87 millionViewN/AView Earnings Details
11/6/2013Q313($0.14)($0.09)$1.61 million$1.60 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.16)($0.07)$1.48 million$1.60 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.17)($0.22)$1.73 million$1.37 millionViewN/AView Earnings Details
3/14/2013Q4 2012($4.20)($2.40)ViewN/AView Earnings Details
11/8/2012Q312($0.02)($0.30)$23.87 millionViewN/AView Earnings Details
8/6/2012Q2 2012($0.80)($4.26)ViewN/AView Earnings Details
5/3/2012Q1 2012($2.80)($3.64)ViewN/AView Earnings Details
3/14/2012Q4 2011($2.60)($2.50)ViewN/AView Earnings Details
11/10/2011Q3 2011($2.80)$0.74ViewN/AView Earnings Details
8/15/2011Q2 2011($2.60)($3.44)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.80)($1.82)ViewN/AView Earnings Details
5/14/2008Q1 2008($10.00)($6.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Cleveland BioLabs (NASDAQ:CBLI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Cleveland BioLabs (NASDAQ CBLI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 3.91%
Insider Trading History for Cleveland BioLabs (NASDAQ:CBLI)
Institutional Ownership by Quarter for Cleveland BioLabs (NASDAQ:CBLI)

Cleveland BioLabs (NASDAQ CBLI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22View SEC Filing  
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10View SEC Filing  
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00View SEC Filing  
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00View SEC Filing  
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Cleveland BioLabs (NASDAQ CBLI) News Headlines

Source:
DateHeadline
Charles River Laboratories (CRL) and Cleveland BioLabs (CBLI) Critical AnalysisCharles River Laboratories (CRL) and Cleveland BioLabs (CBLI) Critical Analysis
www.americanbankingnews.com - April 20 at 3:34 PM
Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Being Overpaid?Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Being Overpaid?
finance.yahoo.com - April 17 at 4:42 PM
Cleveland BioLabs (CBLI) Upgraded to Hold by ValuEngineCleveland BioLabs (CBLI) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Cleveland BioLabs, Inc: Cleveland Biolabs Announces Progress on European Marketing Authorization ApplicationCleveland BioLabs, Inc: Cleveland Biolabs Announces Progress on European Marketing Authorization Application
www.finanznachrichten.de - March 29 at 10:05 AM
Cleveland Biolabs Announces Progress on European Marketing Authorization ApplicationCleveland Biolabs Announces Progress on European Marketing Authorization Application
finance.yahoo.com - March 29 at 10:05 AM
Cleveland Biolabs Reports 2017 Financial Results and Development ProgressCleveland Biolabs Reports 2017 Financial Results and Development Progress
finance.yahoo.com - March 6 at 9:31 AM
Reviewing Cleveland BioLabs (CBLI) & Chromadex (CDXC)Reviewing Cleveland BioLabs (CBLI) & Chromadex (CDXC)
www.americanbankingnews.com - February 28 at 5:08 AM
Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?Should You Be Concerned About Cleveland BioLabs Inc’s (NASDAQ:CBLI) Investors?
finance.yahoo.com - February 21 at 4:32 PM
Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)?Have Investors Already Priced In Healthcare Growth For Cleveland BioLabs Inc (NASDAQ:CBLI)?
finance.yahoo.com - February 9 at 5:33 PM
Critical Survey: Cleveland BioLabs (CBLI) versus Abeona Therapeutics (ABEO)Critical Survey: Cleveland BioLabs (CBLI) versus Abeona Therapeutics (ABEO)
www.americanbankingnews.com - January 23 at 9:30 AM
Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Incentives Align With Yours?Is Cleveland BioLabs Inc’s (NASDAQ:CBLI) CEO Incentives Align With Yours?
finance.yahoo.com - January 1 at 4:54 PM
Cleveland BioLabs (CBLI) & Agenus (AGEN) Head-To-Head SurveyCleveland BioLabs (CBLI) & Agenus (AGEN) Head-To-Head Survey
www.americanbankingnews.com - January 1 at 1:22 PM
ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017ETFs with exposure to Cleveland BioLabs, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 4:55 PM
Is Cleveland BioLabs Inc (NASDAQ:CBLI) As Financially Strong As Its Balance Sheet Indicates?Is Cleveland BioLabs Inc (NASDAQ:CBLI) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - December 22 at 8:07 PM
ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017ETFs with exposure to Cleveland BioLabs, Inc. : December 13, 2017
finance.yahoo.com - December 13 at 5:08 PM
Cleveland BioLabs (CBLI) versus The Competition Critical ReviewCleveland BioLabs (CBLI) versus The Competition Critical Review
www.americanbankingnews.com - December 5 at 9:26 PM
Cleveland BioLabs (CBLI) Stock Rating Lowered by ValuEngineCleveland BioLabs (CBLI) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - December 3 at 7:58 PM
ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017ETFs with exposure to Cleveland BioLabs, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:57 PM
Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:00 AM
What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like?What Does Cleveland BioLabs Inc’s (CBLI) Ownership Structure Look Like?
finance.yahoo.com - November 22 at 10:44 PM
ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017ETFs with exposure to Cleveland BioLabs, Inc. : November 15, 2017
finance.yahoo.com - November 16 at 12:26 PM
Cleveland BioLabs, Inc. (CBLI) Posts Quarterly  Earnings ResultsCleveland BioLabs, Inc. (CBLI) Posts Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 12:56 PM
Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development ProgressCleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
finance.yahoo.com - November 14 at 5:29 PM
Financial Contrast: Cleveland BioLabs (CBLI) versus Its PeersFinancial Contrast: Cleveland BioLabs (CBLI) versus Its Peers
www.americanbankingnews.com - November 13 at 11:28 AM
How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector?How Does Cleveland BioLabs Inc (CBLI) Compare To The Healthcare Sector?
finance.yahoo.com - November 8 at 7:59 PM
ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017ETFs with exposure to Cleveland BioLabs, Inc. : October 26, 2017
finance.yahoo.com - October 26 at 5:11 PM
Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI)Head to Head Survey: Curis (CRIS) and Cleveland BioLabs (CBLI)
www.americanbankingnews.com - October 13 at 8:32 PM
ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017ETFs with exposure to Cleveland BioLabs, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 6:31 PM
ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017ETFs with exposure to Cleveland BioLabs, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 10:01 PM
Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Cleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 5:17 PM
Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)
www.americanbankingnews.com - September 17 at 2:31 AM
What You Must Know About Cleveland BioLabs Inc’s (CBLI) RisksWhat You Must Know About Cleveland BioLabs Inc’s (CBLI) Risks
finance.yahoo.com - September 11 at 5:34 PM
Cleveland BioLabs, Inc. (CBLI) Posts  Earnings ResultsCleveland BioLabs, Inc. (CBLI) Posts Earnings Results
www.americanbankingnews.com - August 15 at 9:41 AM
Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market PotentialCleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential
finance.yahoo.com - August 11 at 5:26 PM
ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017ETFs with exposure to Cleveland BioLabs, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 10:18 PM
ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017ETFs with exposure to Cleveland BioLabs, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:35 PM
Cleveland BioLabs Reports First Quarter 2017 Financial Results and Development ProgressCleveland BioLabs Reports First Quarter 2017 Financial Results and Development Progress
feeds.benzinga.com - May 15 at 8:01 AM
Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...Gainers & Losers Of Apr.19: SNGX, IMGN, CBLI, SSH, AKTX...
www.finanznachrichten.de - April 19 at 11:03 PM
Cleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-PlusCleveland BioLabs, Inc. (CBLI) Stock Tacks On Another 40%-Plus
investorplace.com - April 19 at 3:33 PM
Cleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA ReviewCleveland Biolabs (CBLI) to Begin In Vivo Bio-Comparability Study Following FDA Review
www.streetinsider.com - April 19 at 1:01 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh
biz.yahoo.com - February 22 at 9:21 PM
Cleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoDCleveland Biolabs (CBLI) Announces $1.1M JWMRP Contract Modification with U.S. DoD
www.streetinsider.com - October 12 at 8:37 AM
BRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of DefenseBRIEF-Cleveland BioLabs announces a $1.1 mln cost realignment with Department of Defense
www.reuters.com - October 11 at 4:13 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal OfficersCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - July 22 at 4:22 PM
CLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StaCLEVELAND BIOLABS INC Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta
biz.yahoo.com - July 21 at 6:05 AM
CLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StandCLEVELAND BIOLABS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Stand
biz.yahoo.com - July 12 at 4:25 PM
22nd Century to begin cannabis research at new medical campus labs22nd Century to begin cannabis research at new medical campus labs
www.bizjournals.com - May 12 at 2:40 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit
biz.yahoo.com - May 6 at 5:55 PM
CLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersCLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - April 15 at 3:05 PM
GLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A SnagGLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag
www.rttnews.com - March 17 at 2:04 AM

SEC Filings

Cleveland BioLabs (NASDAQ:CBLI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Cleveland BioLabs (NASDAQ:CBLI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Cleveland BioLabs (NASDAQ CBLI) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.